The Effectiveness of Ultrasound Guided Ozone (O2-O3) Injection With Knee Osteoarthritis

Last updated: March 15, 2022
Sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Osteoarthritis

Knee Injuries

Treatment

N/A

Clinical Study ID

NCT04830423
13
  • Ages 45-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Knee ostheoarthritis (KOA) is a common disabling and degenerative disease leading to painful joints, articular stiffness, and decreased function. The mechanism of the ozone of relieving the pain and improving the knee function is through inhibiting the inflammation reaction in the KOA directly. Actually, the ozone intra-articular injection had been used to relieve the pain caused by KOA.

The aim of this study is to evaluate the effect of intra-articular injection of medical ozone given into the knee of the osteoarthritis patients, and to compare it with intra-articular steroid injection and to investigate the effectiveness of ozone and steroid the job to determine the superiority of the injections to each other.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Female / male aged> 45 years
  2. Diagnosis of knee ostheoarthritis after physical examination and imaging (directradiography)
  3. Those whose symptoms persist> 6 months
  4. Radiological staging of osteoarthritis according to the Kellgren-Lawrence scale Grade 2 and 3
  5. Participation in the study voluntarily and regularly

Exclusion

Exclusion Criteria:

  1. History of previous knee surgery
  2. Patients with inflammatory arthritis (Rheumatoid arthritis, psoriatic arthritis, goutyarthritis as)
  3. Patients with neuropathic pain
  4. Those with pain reflected from the waist or hip
  5. History of tumor, infectious, psychiatric illness, bleeding diathesis
  6. Trauma history within the last 6 months
  7. Hyaluronic acid or steroid injection in the last 3 months
  8. Those with systemic diseases such as diabetes, rheumatoid arthritis, hepatitis,coagulopathy
  9. Those with malignant hypertension
  10. Those with G6PDH (Glucose 6-Phosphate Dehydrogenase) deficiency
  11. Those with Graves' disease
  12. Those with cerebrovascular event disease in which bleeding continues actively

Study Design

Total Participants: 96
Study Start date:
April 15, 2021
Estimated Completion Date:
April 15, 2022

Study Description

The study was designed as prospective, randomized, controlled trial. 96 people who met the inclusion criteria were randomized into two groups of people. The first group will be designated as Ozone group will be applied to these patients. Patients in the second group will be designated as the steroid group, and injections will be applied in accordance with protocol. Participants were evaluated with Visual Analogue Scale (VAS), The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The presence of suprapatellar effusion of the participants whose evaluations are completed will be evaluated by ultrasonography and the findings will be recorded. Initial evaluations of the participants will be made before the first injection. Patients in the ozone (O2-O3) injection group will be given intraarticular and per-articular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.

Connect with a study center

  • Sefa

    Ankara, 06660
    Turkey

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.